229 related articles for article (PubMed ID: 26649870)
1. Dose Reduction of Caspofungin in Intensive Care Unit Patients with Child Pugh B Will Result in Suboptimal Exposure.
Martial LC; Brüggemann RJ; Schouten JA; van Leeuwen HJ; van Zanten AR; de Lange DW; Muilwijk EW; Verweij PE; Burger DM; Aarnoutse RE; Pickkers P; Dorlo TP
Clin Pharmacokinet; 2016 Jun; 55(6):723-33. PubMed ID: 26649870
[TBL] [Abstract][Full Text] [Related]
2. Dosing of caspofungin based on a pharmacokinetic/pharmacodynamic index for the treatment of invasive fungal infections in critically ill patients on continuous venovenous haemodiafiltration.
Pérez-Pitarch A; Ferriols-Lisart R; Aguilar G; Ezquer-Garín C; Belda FJ; Guglieri-López B
Int J Antimicrob Agents; 2018 Jan; 51(1):115-121. PubMed ID: 28666752
[TBL] [Abstract][Full Text] [Related]
3. Population Pharmacokinetic Model and Pharmacokinetic Target Attainment of Micafungin in Intensive Care Unit Patients.
Martial LC; Ter Heine R; Schouten JA; Hunfeld NG; van Leeuwen HJ; Verweij PE; de Lange DW; Pickkers P; Brüggemann RJ
Clin Pharmacokinet; 2017 Oct; 56(10):1197-1206. PubMed ID: 28144840
[TBL] [Abstract][Full Text] [Related]
4. Impact of Loading Dose of Caspofungin in Pharmacokinetic-Pharmacodynamic Target Attainment for Severe Candidiasis Infections in Patients in Intensive Care Units: the CASPOLOAD Study.
Bailly S; Gautier-Veyret E; Lê MP; Bouadma L; Andremont O; Neuville M; Mourvillier B; Sonneville R; Magalhaes E; Lebut J; Radjou A; Smonig R; Wolff M; Massias L; Dupuis C; Timsit JF
Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32958709
[TBL] [Abstract][Full Text] [Related]
5. Low Caspofungin Exposure in Patients in Intensive Care Units.
van der Elst KC; Veringa A; Zijlstra JG; Beishuizen A; Klont R; Brummelhuis-Visser P; Uges DR; Touw DJ; Kosterink JG; van der Werf TS; Alffenaar JC
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27855112
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetics/pharmacodynamics of micafungin against Candida species in obese, critically ill, and morbidly obese critically ill patients.
Maseda E; Grau S; Luque S; Castillo-Mafla MP; Suárez-de-la-Rica A; Montero-Feijoo A; Salgado P; Gimenez MJ; García-Bernedo CA; Gilsanz F; Roberts JA
Crit Care; 2018 Apr; 22(1):94. PubMed ID: 29655372
[TBL] [Abstract][Full Text] [Related]
7. Assessment of echinocandin regimens by pharmacokinetic/pharmacodynamic analysis against Candida spp. in paediatric patients.
Xu G; Zhu L; Liao S; Ge T; Yang J
Int J Antimicrob Agents; 2015 Dec; 46(6):631-41. PubMed ID: 26602452
[TBL] [Abstract][Full Text] [Related]
8. Whole-body physiology-based pharmacokinetics of caspofungin for general patients, intensive care unit patients and hepatic insufficiency patients.
Yang QT; Zhai YJ; Chen L; Zhang T; Yan Y; Meng T; Liu LC; Chen LM; Wang X; Dong YL
Acta Pharmacol Sin; 2018 Sep; 39(9):1533-1543. PubMed ID: 29849129
[TBL] [Abstract][Full Text] [Related]
9. Caspofungin Population Pharmacokinetics in Critically Ill Patients Undergoing Continuous Veno-Venous Haemofiltration or Haemodiafiltration.
Roger C; Wallis SC; Muller L; Saissi G; Lipman J; Brüggemann RJ; Lefrant JY; Roberts JA
Clin Pharmacokinet; 2017 Sep; 56(9):1057-1068. PubMed ID: 28035589
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic/pharmacodynamic adequacy of echinocandins against Candida spp. in intensive care unit patients and general patient populations.
Yang Q; Wang T; Xie J; Wang Y; Zheng X; Chen L; Li Y; Meng T; Dong Y
Int J Antimicrob Agents; 2016 May; 47(5):397-402. PubMed ID: 27068676
[TBL] [Abstract][Full Text] [Related]
11. A Multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis.
Betts RF; Nucci M; Talwar D; Gareca M; Queiroz-Telles F; Bedimo RJ; Herbrecht R; Ruiz-Palacios G; Young JA; Baddley JW; Strohmaier KM; Tucker KA; Taylor AF; Kartsonis NA;
Clin Infect Dis; 2009 Jun; 48(12):1676-84. PubMed ID: 19419331
[TBL] [Abstract][Full Text] [Related]
12. Invasive candidiasis treated in the intensive care unit: observations from a randomized clinical trial.
DiNubile MJ; Lupinacci RJ; Strohmaier KM; Sable CA; Kartsonis NA
J Crit Care; 2007 Sep; 22(3):237-44. PubMed ID: 17869975
[TBL] [Abstract][Full Text] [Related]
13. Caspofungin Weight-Based Dosing Supported by a Population Pharmacokinetic Model in Critically Ill Patients.
Märtson AG; van der Elst KCM; Veringa A; Zijlstra JG; Beishuizen A; van der Werf TS; Kosterink JGW; Neely M; Alffenaar JW
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32660990
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetic model-guided optimization of intravenous voriconazole dosing regimens in critically ill patients with liver dysfunction.
Lin XB; Lui KY; Guo PH; Liu XM; Liang T; Hu XG; Tong L; Wu JJ; Xia YZ; Chen P; Zhong GP; Chen X; Cai CJ
Pharmacotherapy; 2022 Jan; 42(1):23-33. PubMed ID: 34655497
[TBL] [Abstract][Full Text] [Related]
15. Assessment of micafungin regimens by pharmacokinetic-pharmacodynamic analysis: a dosing strategy for Aspergillus infections.
Ikawa K; Nomura K; Morikawa N; Ikeda K; Taniwaki M
J Antimicrob Chemother; 2009 Oct; 64(4):840-4. PubMed ID: 19700475
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics of micafungin in ICU patients with sepsis and mechanical ventilation.
Jullien V; Azoulay E; Schwebel C; Le Saux T; Charles PE; Cornet M; Souweine B; Klouche K; Jaber S; Trouillet JL; Bruneel F; Cour M; Cousson J; Meziani F; Gruson D; Paris A; Darmon M; Garrouste-Orgeas M; Navellou JC; Foucrier A; Allaouchiche B; Das V; Gangneux JP; Ruckly S; Wolff M; Timsit JF;
J Antimicrob Chemother; 2017 Jan; 72(1):181-189. PubMed ID: 27609051
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic Properties of Micafungin in Critically Ill Patients Diagnosed with Invasive Candidiasis.
Boonstra JM; van der Elst KC; Veringa A; Jongedijk EM; Brüggemann RJ; Koster RA; Kampinga GA; Kosterink JG; van der Werf TS; Zijlstra JG; Touw DJ; Alffenaar JWC
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28971861
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic/Pharmacodynamic Target Attainment of Different Antifungal Agents in De-escalation Treatment in Critically Ill Patients: a Step toward Dose Optimization Using Monte Carlo Simulation.
Xie J; Yang Q; Han X; Dong Y; Zhang T; Li Y; Ji M; Liu C; Cai Y; Wang Y
Antimicrob Agents Chemother; 2022 Jun; 66(6):e0009922. PubMed ID: 35604209
[TBL] [Abstract][Full Text] [Related]
19. Echinocandin use in the neonatal intensive care unit.
Caudle KE; Inger AG; Butler DR; Rogers PD
Ann Pharmacother; 2012 Jan; 46(1):108-16. PubMed ID: 22190252
[TBL] [Abstract][Full Text] [Related]
20. Micafungin pharmacokinetic/pharmacodynamic adequacy for the treatment of invasive candidiasis in critically ill patients on continuous venovenous haemofiltration.
Maseda E; Grau S; Villagran MJ; Hernandez-Gancedo C; Lopez-Tofiño A; Roberts JA; Aguilar L; Luque S; Sevillano D; Gimenez MJ; Gilsanz F
J Antimicrob Chemother; 2014 Jun; 69(6):1624-32. PubMed ID: 24505092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
